Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) EBT Margin (2016 - 2024)

Historic EBT Margin for Summit Therapeutics (SMMT) over the last 6 years, with Q3 2022 value amounting to 7700.0%.

  • Summit Therapeutics' EBT Margin changed N/A to 7700.0% in Q3 2022 from the same period last year, while for Dec 2024 it was 2943.23%, marking a year-over-year increase of 5.5651520379798105e22%. This contributed to the annual value of 11174.75% for FY2022, which is 62769100.0% down from last year.
  • Per Summit Therapeutics' latest filing, its EBT Margin stood at 7700.0% for Q3 2022.
  • In the past 5 years, Summit Therapeutics' EBT Margin ranged from a high of 71.5% in Q3 2018 and a low of 7700.0% during Q3 2022
  • Moreover, its 4-year median value for EBT Margin was 1518.71% (2018), whereas its average is 2587.66%.
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 1733600bps in 2018, then crashed by -50088000bps in 2019.
  • Summit Therapeutics' EBT Margin (Quarter) stood at 1392.35% in 2018, then plummeted by -349bps to 6255.65% in 2019, then soared by 63bps to 2296.25% in 2020, then plummeted by -235bps to 7700.0% in 2022.
  • Its last three reported values are 7700.0% in Q3 2022, 2296.25% for Q1 2020, and 6255.65% during Q4 2019.